SEALED AIR CORP/DE — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SEALED AIR CORP/DE filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.36B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $5.39B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $5.49B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $5.64B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $5.53B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $4.90B | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | $1.30B | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $1.22B | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $1.16B | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $1.11B | Mar 2, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.33B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $5.35B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $5.44B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $5.61B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $5.49B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $4.87B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $4.76B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $4.70B | Feb 25, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.23B | Feb 21, 2018 |
| FY2017 | Sep 30, 2017 | $1.13B | Feb 21, 2018 |
| FY2017 | Jun 30, 2017 | $1.07B | Feb 21, 2018 |
| FY2017 | Mar 31, 2017 | $1.03B | Feb 21, 2018 |
| FY2017 | Dec 31, 2016 | $1.10B | Feb 21, 2018 |
| FY2017 | Sep 30, 2016 | $1.07B | Feb 21, 2018 |
| FY2017 | Jun 30, 2016 | $1.04B | Feb 21, 2018 |
| FY2017 | Mar 31, 2016 | $1.01B | Feb 21, 2018 |
| FY2016 | Dec 31, 2015 | $1.75B | Feb 15, 2017 |
| FY2016 | Sep 30, 2015 | $1.75B | Feb 15, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.60B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.63B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $1.64B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $1.77B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.68B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.61B | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | $429.30M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $392.00M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $378.30M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $365.20M | Mar 2, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $505.50M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $264.70M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $341.60M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $491.60M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $506.80M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $502.90M | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | $104.30M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $68.00M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $33.20M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $57.50M | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $725.70M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $735.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $754.60M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $944.80M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $900.90M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $788.10M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $578.50M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $656.30M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $571.30M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $628.90M | Feb 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $93.40M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $96.90M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $102.50M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $99.80M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $95.90M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $77.30M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $80.80M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $91.80M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $88.00M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $744.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $752.60M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $759.10M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $786.20M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $772.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $773.70M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $913.30M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $782.30M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $815.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $754.30M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $628.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $728.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $516.20M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $613.30M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $709.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $737.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $511.10M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $428.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $424.40M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $906.90M | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $169.50M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $220.20M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $244.20M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $237.30M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $213.10M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $181.10M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $189.70M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $168.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $183.80M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $275.70M | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.01B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $7.02B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $7.20B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $6.21B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $6.23B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $6.08B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $5.77B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.05B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $5.28B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $7.42B | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.78B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $6.40B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $6.65B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $5.87B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.98B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $5.91B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $5.96B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.40B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $5.13B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $6.81B | Feb 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.24B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $624.50M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $549.50M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $344.10M | Mar 2, 2026 |
| FY2022 | Dec 31, 2021 | $248.70M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $172.50M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | ($196.20M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($348.60M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $152.30M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $609.70M | Feb 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.90B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $2.88B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $2.89B | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $2.17B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $2.19B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $2.22B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $2.22B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $1.95B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.94B | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $1.88B | Feb 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $643.40M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $496.50M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $3.16B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.79B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $2.40B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.00B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.84B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.74B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $1.04B | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $344.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $371.80M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $346.10M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $456.10M | Feb 26, 2025 |
| FY2024 | Dec 31, 2021 | $561.00M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $548.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $262.40M | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $271.70M | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | $594.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $333.70M | Mar 2, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.94B | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | $4.30B | Feb 26, 2025 |
| FY2023 | Dec 31, 2023 | $4.59B | Feb 27, 2024 |
| FY2022 | Dec 31, 2022 | $3.70B | Feb 21, 2023 |
| FY2021 | Dec 31, 2021 | $3.73B | Feb 22, 2022 |
| FY2020 | Dec 31, 2020 | $3.78B | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $3.75B | Mar 2, 2020 |
| FY2018 | Dec 31, 2018 | $3.27B | Feb 19, 2019 |
| FY2017 | Dec 31, 2017 | $3.26B | Feb 21, 2018 |
| FY2016 | Dec 31, 2016 | $4.30B | Feb 15, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 21, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 147.25M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 145.73M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 144.47M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 144.67M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 148.10M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 154.89M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | 154.51M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 155.65M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | 168.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | 193.48M | Feb 19, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.20M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $118.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $117.90M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $118.50M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $115.60M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $100.40M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $99.10M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $104.10M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $119.70M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $121.60M | Feb 19, 2019 |